Хроническая HCV-инфекция: взгляд интерниста (II часть)


Цитировать

Полный текст

Аннотация

Инфицирование вирусом гепатита С (HCV) приводит к возникновению не только хронического гепатита с последующими осложнениями в виде цирроза печени и гепатоцеллюлярной карциномы, но и значительного числа других заболеваний — так называемых внепеченочных проявлений хронической HCV-инфекции. Помимо лимфопролиферативных и аутоиммунных расстройств, рассмотренных в I части данного обзора, с хронической HCV-инфекцией оказались ассоциированы многие другие заболевания. Анализу связи хронической HCV-инфекции с развитием некоторых болезней эндокринной и таких как тиреоидит и сахарный диабет, а также сердечно-сосудистых заболеваний, посвящена II часть настоящего обзора. В ней также дается характеристика современных противовирусных препаратов и рассматриваются возможности их применения при внепеченочной манифестации хронической HCV-инфекции.

Об авторах

М Л Зубкин

Московский НИИ эпидемиологии и микробиологии им. Г.Н. Габричевского Роспотребнадзора; Филиал Военно-медицинской академии им. С.М. Кирова, Москва

В И Червинко

Филиал Военно-медицинской академии им. С.М. Кирова

Москва, Россия

Ю В Овчинников

Филиал Военно-медицинской академии им. С.М. Кирова

Москва, Россия

Е В Крюков

Главный военный клинический госпиталь им. Н.Н. Бурденко

Москва, Россия

О Н Котенко

Городская клиническая больница №52 Департамента здравоохранения Москвы

Москва, Россия

Список литературы

  1. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117(1):10-13. doi: 10.1016/j.amjmed.2004.01.023
  2. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16(6):563-572. doi: 10.1089/thy.2006.16.563
  3. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Giunti M, Pileri SA, Zignego AL. B-cells and mixed cryoglobulinemia. Autoimmunity Rev. 2007;7(2):114-120. doi: 10.1016/j.autrev.2007.02.019
  4. Mao XR, Zhang LT, Chen H, Xiao P, Zhang YC. Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients. Exper Ther Med. 2014;8(1):133-140. doi: 10.3892/etm.2014.1709
  5. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nature Clin Practice Endocrinol Met. 2009;5(1):26-34. doi: 10.1038/ncpendmet1027
  6. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, Antonelli A, Zignego AL. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepat. 2015;7(3):327-343. doi: 10.4254/wjh.v7.i3.327
  7. Hadziyannis SJ. Nonhepatic manifestations and combined diseases in HCV infection. Digestive Dis Scie. 1996;41:63-74. doi: 10.1007/bf02087878
  8. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM, Jiménez-Rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol. 2008;7(1):72-77.
  9. Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmunity. 2008; 31(4):339-344. doi: 10.1016/j.jaut.2008.08.001
  10. Blackard JT, Kong L, Huber AK, Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid. 2013;23(7):863-870. doi: 10.1089/thy.2012.0507
  11. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronichepatitis and mixed cryoglobulinemia. Autoimmunity Rev. 2008;8(1):18-23. doi: 10.1016/j.autrev.2008.07.017
  12. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine. 2008;42(1):137-143. doi: 10.1016/j.cyto.2008.01.002
  13. Murata M, Nabeshima S, Maeda N, Nakashima H, Kashiwagi S, Hayashi J. Increased frequency of IFN-γ-producing peripheral CD8+ T cells with memoryphenotype in patients with chronic hepatitis C. J Med Virol. 2002;67:162-170. doi: 10.1002/jmv.2205
  14. Matskevich AA, Strayer DS. Exploiting hepatitis C virus activation of NFκB to deliver HCV responsive expression of interferons α and γ. Gene Ther. 2003;10(22):1861-1873. doi: 10.1038/sj.gt.3302091
  15. Antonelli A, Pistello M. New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection and HCV Extrahepatic Manifestations. Cur Drug Targets. 2015;16:1-5. doi: 10.2174/1389450116666151102095708
  16. Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exper Rheumatology. 2002;20(5):693-696.
  17. Montella M Pezzullo L, Crispo A, Izzo F, Amore A, Marone U, Tamburini M, Ronga D, Chiofalo MG, Chiappetta G, Mozzillo N. Risk of thyroid cancer and high prevalence of hepatitis C virus. Oncol Reports. 2003;10(1):133-136. doi: 10.3892/or.10.1.133
  18. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, Marchi S, Ferrannini E. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid. 2007;17:447-451. doi: 10.1089/thy.2006.0194
  19. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma: a study of surgical cases among Japanese, and white and African Americans. Cancer. 1995;76(11):2312-2318. doi: 10.1002/1097-0142(19951201)76:11
  20. Duberg AS, Nordstrцm M, Tцrner A, Reichard O, Strauss R, Janzon R, Bдck E, Ekdahl K. Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology. 2005;41(3):652-659. doi: 10.1002/hep.20608
  21. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepat. 2008;49(5):831-844. doi: 10.1016/j.jhep.2008.08.006
  22. Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009;50(3):697-706. doi: 10.1002/hep.23031
  23. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Alimentary Pharmacol Ther. 2013;37(6):647-652. doi: 10.1111/apt.12234
  24. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38(1):50-56. doi: 10.1053/jhep.2003.50291
  25. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15(3):280-288. doi: 10.3748/wjg.15.280
  26. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford). 2003; 43(2):238-240. doi: 10.1093/rheumatology/keh011
  27. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2005;28(10):2548-2550. doi: 10.2337/diacare.28.10.2548
  28. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus anddyslipidemia among antiretroviral naive patients co-infected with hepatitisC virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 2005;50(4):331-337. doi: 10.1016/j.jinf.2004.06.001
  29. Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. J Viral Hepatitis. 2011;18(7):372-380. doi: 10.1111/j.1365-2893.2011.01439.x
  30. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496-502. doi: 10.1016/j.atherosclerosis.2012.01.051
  31. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clйment S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2011;33:1162-1172. doi: 10.1111/j.1365-2036.2011.04635.x
  32. Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Rev Gastroenterol Hepatol. 2011;5(4):503-516. doi: 10.1586/egh.11.43
  33. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384-1392. doi: 10.1016/j.hep.2003.09.012
  34. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metabol. 2002;87(10):4602-4606. doi: 10.1210/jc.2002-020135
  35. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Investigat. 2006;116(7):1793-1801. doi: 10.1172/jci29069
  36. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R.. Circulating levels of MCP-1 and IL—8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30(9):1347-1355. doi: 10.1038/sj.ijo.0803259
  37. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M.. Hepatitis C virus down-regulatesinsulin receptor substrates 1 and 2 through up-regulation of suppres-sor of cytokine signalling 3. Am J Pathol. 2004;165(5):1499-1508. doi: 10.1016/S0002-9440(10)63408-6
  38. Persico M, Russo R, Persico E, Svelto M, Spano D, Andolfo I, La Mura V, Capasso M, Tiribelli C, Torella R, Iolascon A. SOCS3 and IRS-1 gene expression differsbetween genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clin Chem Lab Med. 2009;47(10):1217-1225. doi: 10.1515/CCLM.2009.280
  39. Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- in Huh-7 cells. J General Virol. 2010;91(7):1678-1686. doi: 10.1099/vir.0.020644-0
  40. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Digest Liver Dis. 2016;48(2):105-111. doi: 10.1016/j.dld.2015.10.016
  41. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Reviews in basic and clinical gastroenterology and hepatology.Gastroenterology. 2015;49(6):1345-1360. doi: 10.1053/j.gastro.2015.08.035
  42. Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010;138(3):932-941. doi: 10.1053/j.gastro.2009.11.050
  43. Masini M Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, Del Prato S, Mosca F, Filipponi F, Marchetti P. Hepatitis C virus infection and human pancreatic β-cell dysfunction. Diabetes Care. 2005;28(4):940-941. doi: 10.2337/diacare.28.4.940
  44. Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35(12):981-989. doi: 10.1089/jir.2014.0200
  45. Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T, Eguchi Y, Ozaki I, Hisatomi A, Fujimoto K. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinemia in patients with chronic hepatitis C. Liver International. 2009;29(6): 871-877. doi: 10.1111/j.1478-3231.2009.01993.x
  46. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT;. Reduction of insulin resistance with effective clearance of Hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(5):458-562. doi: 10.1016/j.cgh.2010.01.022
  47. Aghemo A, Prati GM, Rumi MG, Soffredini R, D’Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56(5):1681-1687. doi: 10.1002/hep.25867
  48. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570-576. doi: 10.1111/j.1572-0241.2006.01038.x
  49. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125(3):1695-1704. doi: 10.1053/j.gastro.2003.08.032
  50. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L.. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105(9):1970-1977. doi: 10.1038/ajg.2010.110
  51. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Alimentary Pharmacol Ther. 2011;34(3):297-305. doi: 10.1111/j.1365-2036.2011.04716.x
  52. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739-744. doi: 10.1002/hep.22703
  53. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59(4):1293-1302. doi: 10.1002/hep.26892
  54. Mostafa A, Mohamed MK, Saeed M, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, Esmat G, El-Hoseiny M, Abdul-Hamid M,Hughes A, Chaturvedi N. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010;59(8):1135-1140. doi: 10.1136/gut.2009.202317
  55. Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, Licata A, Marchesini G, Mazzola A, Parrinello G, Novo S, Licata G, Craxì A. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology. 2012;55(5):1317-1323. doi: 10.1002/hep.25508
  56. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS ONE. 2012;7(2):e31527. doi: 10.1371/journal.pone.0031527
  57. He H, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS ONE. 2013;8(11):e81305. doi: 10.1371/journal.pone.0081305
  58. Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, Mehta JL. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol. 2014;114(12):1841-1845. doi: 10.1016/j.amjcard.2014.09.020
  59. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49(1):9-16. doi: 10.1016/j.jhep.2008.03.016
  60. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49(2):225-232. doi: 10.1086/599371
  61. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, Rossi L, Pratesi C, Gensini GF, Paperetti L, Zignego AL. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47(1):72-75. doi: 10.1016/j.jcv.2009.10.005
  62. Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology. 2012;142:634-643. doi: 10.1053/j.gastro.2011.11.028
  63. Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis. 2013;231(1):22-26. doi: 10.1016/j.atherosclerosis.2013.08.003
  64. Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410-3417. doi: 10.3748/wjg.v20.i13.3410
  65. Vivona N, Bivona G, Noto D, Sasso BL, Cefalù AB, Chiarello G, Falletta A, Ciaccio M, Averna MR. C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clin Biochem. 2009;42(16-17):1713-1718. doi: 10.1016/j.clinbiochem.2009.08.014
  66. Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ,Pereira LM, Alvares-da-Silva MR. Effect of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2013;164(2):221-226. doi: 10.1016/j.ijcard.2011.07.016
  67. Pateria P, Jeffrey GP, MacQuillan G, Speers D, Ching H, Chinnaratha MA, Watts GF, Adams LA .The association between chronic hepatitis C infection and cardiovascular risk. Intl Med J. 2016;46(1):63-70. doi: 10.1111/imj.12936
  68. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, Petrobelli F. Carotid and femoral atherosclerosis in chronic hepatitis C: a 5-year follow-up. Angiology 2008;59(6):717-720. doi: 10.1177/0003319707311536
  69. Forde KA, Haynes K, Troxel AB, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V . Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepatitis. 2012;19:271-277. doi: 10.1111/j.1365-2893.2011.01545.x
  70. Hsu Y-C, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495-503. doi: 10.1136/gutjnl-2014-308163
  71. Hsu С-S, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS.. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Alimentary Pharmacol Ther. 2013;38(4):415-423. doi: 10.1111/apt.12391
  72. Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410-3417. doi: 10.3748/wjg.v20.i13.3410
  73. Maruyama S, Koda Ma, Oyake N, Sato H, Fujii Y,Horie Y, Murawaki Y. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58(1):11-15. doi: 10.1016/j.jhep.2012.07.045
  74. Omura T, Yoshiyama M, Hayashi T, Nishiguchi S, Kaito M, Horiike S, Fukuda K, Inamoto S, Kitaura Y, Nakamura Y, Teragaki M, Tokuhisa T, Iwao H, Takeuchi K, Yoshikawa J. Core protein of hepatitis C virus induced cardiomyopathy. Circulation Res. 2005;96(2):148-150. doi: 10.1161/01.res.0000154263.70223.13
  75. Ferri C, Bertozzi MA, Zignego AL. Erectile dysfunction and hepatitis C virus infection. JAMA. 2002;288(6):698-699. doi: 10.1001/jama.288.6.698
  76. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Тихонов И.Н., Федосьина Е.А., Павлов Ч.С. Алгоритмы диагностики и лечения в гепатологии Справочные материалы. М.: МЕДпресс-информ; 2016.
  77. EASL Recommendations on Treatment of Hepatitis C 2015. JHepatol. 2015;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025
  78. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-954. doi: 10.1002/hep.27950
  79. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P.Twelve weeks posttreatment follow-up is as relevant as 24 weeks todetermine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122-1126. doi: 10.1002/hep.23444
  80. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(l):69-78. doi: 10.1111/liv.12423
  81. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132(5):1979-1998. doi: 10.1053/j.gastro.2007.03.116
  82. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investigat Drugs. 2013; 22(9):1107-1121. doi: 10.1517/13543784.2013.806482
  83. Maruyama A, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2015;0:1-6. doi: 10.1093/ndt/gfv361
  84. Hill L. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Topics Antiviral Med. 2015;23(2):92-96.
  85. Saadoun D, Thibault V, Si Ahmed SN, Alric L Mallet M, Guillaud C, Izzedine H, Plaisier A, Fontaine H, Costopoulos M Le Garff-Tavernier M, Hezode C, Pol S, Musset L, Poynard T, Cacoub P. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2015;0:1-6. doi: 10.1136/annrheumdis-2015-208339
  86. Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016; 63(2):408-417. doi: 10.1002/hep.28297
  87. Emeri JS, Kuczynski M, La D, Kowgier M, Feld J. Treatment of hepatitis C associated mixed cryoglobulinemia with direct acting antiviral therapy. J Hepatol. 2016 64(2):779.
  88. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis. Am J Med. 2015;128(9):950-955. doi: 10.1016/j.amjmed.2015.02.017
  89. Carrier P, Jaccard A, Jacques J, Tabouret T, Debette-Gratien M, Abraham J, Mesturoux L, Marquet P, Alain S, Sautereau D, Essig M, Loustaud-Ratti V. Liver Int. 2015;35(10):2222-2227. doi: 10.1111/liv.12897
  90. de Clerck F, Geerts A, Brochez L, Speeckaert R, Boterberg T, Van Vlierberghe H, Verhelst X. Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. J Clin Gastroenterol. 2016;50(5):438. doi: 10.1097/MCG.0000000000000506
  91. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010;59(12):1694-1698. doi: 10.1136/gut.2010.219089
  92. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Lonjon-Domanec I, DeMasi R, Picchio G, Beumont M, Marcellin P. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut. 2012;61(10):1473-1480. doi: 10.1136/gutjnl-2011-300749
  93. Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology. 2013;58(6):1897-1906. doi: 10.1002/hep.26437

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах